2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases
2003
Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens
Blumenschein GR, Herbst RS. Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens. Clinical Lung Cancer 2003, 4: 217-223. PMID: 14624709, DOI: 10.3816/clc.2003.n.001.Peer-Reviewed Original ResearchLung cancerTargeted therapyCell lung cancerReceptor-targeted therapyLung cancer casesHigh mortality rateSpecific biologic pathwaysAdvanced NSCLCChemotherapy regimensCell cycle inhibitionMost patientsCommon malignancyPoor prognosisCancer casesTherapeutic improvementRadiation therapyEncouraging activityNew agentsMortality rateAngiogenesis inhibitionSingle agentClinical testingSurvival rateTherapyTargeted therapeutics